Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegamotecan in Advanced Stomach or GE Junction Cancer
NCT00080002Phase 2Terminated
- Sponsor
- Enzon Pharmaceuticals
- Start
- Dec 2003
- Modality
- Polymer-based Nanoparticles, Small Molecules, Peptide-Drug Conjugates
01
Overview
A Phase 2 trial of pegamotecan in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Enzon Pharmaceuticals. Started Dec 2003; status: terminated.
02
Drugs
pegamotecan
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT00080002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00080002.